About MannKind

MannKind Corporation (Nasdaq and TASE: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients.

In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >


                    follow me on twitter       find us on facebook

Worldwide rights to AFREZZA have been licensed to Sanofi. For more information about AFREZZA, please visit www.Afrezza.com.


Matthew J. Pfeffer, CEO/CFO and Raymond W. Urbanski, CMO held a conference on February 3 to provide a company update.  To view the slide deck Click Here


To view the FAQ: Technosphere® licensing agreement announced by MannKind™, January 21, 2016. Click Here

News & Events

Jan 27, 2016 MannKind Corporation to Hold Investor Conference Call on February 3, 2016 More >
Jan 21, 2016 MannKind Enters Into Collaboration and License Agreement More >
Jan 11, 2016 MannKind Provides Update on Senior Management More >